Neurobiology of Aging
Volume 28, Issue 5 , Pages 742-747 , May 2007

CSF neurofilament light chain and tau differentiate multiple system atrophy from Parkinson's disease

  • W. Farid Abdo

      Affiliations

    • Department of Neurology, Radboud University, Nijmegen Medical Centre, The Netherlands
    • Corresponding Author InformationCorresponding author at: Parkinson Centre Nijmegen (ParC), Department of Neurology (935), Radboud University, Nijmegen Medical Centre, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands. Tel.: +31 24 3615202; fax: +31 243541122.
    • ,
  • Bastiaan R. Bloem

      Affiliations

    • Department of Neurology, Radboud University, Nijmegen Medical Centre, The Netherlands
    • ,
  • Wieneke J. Van Geel

      Affiliations

    • Laboratory of Pediatrics and Neurology, Radboud University, Nijmegen Medical Centre, The Netherlands
    • ,
  • Rianne A.J. Esselink

      Affiliations

    • Department of Neurology, Radboud University, Nijmegen Medical Centre, The Netherlands
    • Department of Geriatrics, Radboud University, Nijmegen Medical Centre, The Netherlands
    • ,
  • Marcel M. Verbeek

      Affiliations

    • Department of Neurology, Radboud University, Nijmegen Medical Centre, The Netherlands
    • Laboratory of Pediatrics and Neurology, Radboud University, Nijmegen Medical Centre, The Netherlands

Received 19 September 2005 ,Revised 23 January 2006 ,Accepted 21 March 2006.

References 

  1. Abdo WF, de Jong D, Hendriks JCM, Horstink MWIM, Kremer BPH, Bloem BR, et al. Cerebrospinal fluid analysis differentiates multiple system atrophy from Parkinson's disease. Mov Disord. 2004;19(5):571–579
  2. Brautigam C, Wevers RA, Jansen RJ, Smeitink JA, de Rijk-van Andel JF, Gabreels FJ, et al. Biochemical hallmarks of tyrosine hydroxylase deficiency. Clin Chem. 1998;44(9):1897–1904
  3. Fuchs E, Cleveland DW. A structural scaffolding of intermediate filaments in health and disease. Science. 1998;279(5350):514–519
  4. Goedert M. Alpha-synuclein and neurodegenerative diseases. Nat Rev Neurosci. 2001;2(7):492–501
  5. Holmberg B, Rosengren L, Karlsson JE, Johnels B. Increased cerebrospinal fluid levels of neurofilament protein in progressive supranuclear palsy and multiple-system atrophy compared with Parkinson's disease. Mov Disord. 1998;13(1):70–77
  6. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55(3):181–184
  7. Litvan I, Bhatia KP, Burn DJ, Goetz CG, Lang AE, McKeith I, et al. Movement disorders society scientific issues committee report: SIC task force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov Disord. 2003;18(5):467–486
  8. Lycke JN, Karlsson JE, Andersen O, Rosengren LE. Neurofilament protein in cerebrospinal fluid: a potential marker of activity in multiple sclerosis. J Neurol Neurosurg Psychiat. 1998;64(3):402–404
  9. Mathias CJ WAC. The Shy-Drager syndrome (and multiple system atrophy). In:  Calne DB editors. Neurodegenerative diseases. Philadelphia: WB Saunders; 1994;p. 743–767
  10. Molina JA, ito-Leon J, Jimenez-Jimenez FJ, Orti-Pareja M, Berbel A, Tallon-Barranco A, et al. Tau protein concentrations in cerebrospinal fluid of non-demented Parkinson's disease patients. Neurosci Lett. 1997;238(3):139–141
  11. Papp MI, Kahn JE, Lantos PL. Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome). J Neurol Sci. 1989;94(1–3):79–100
  12. Petzold A, Keir G, Green AJ, Giovannoni G, Thompson EJ. A specific ELISA for measuring neurofilament heavy chain phosphoforms. J Immunol Meth. 2003;278(1/2):179–190
  13. Polinsky RJ, Holmes KV, Brown RT, Weise V. CSF acetylcholinesterase levels are reduced in multiple system atrophy with autonomic failure. Neurology. 1989;39(1):40–44
  14. Polinsky RJ, Jimerson DC, Kopin IJ. Chronic autonomic failure: CSF and plasma 3-methoxy-4-hydroxyphenylglycol. Neurology. 1984;34(7):979–983
  15. Rajput AH, Rozdilsky B, Rajput A. Accuracy of clinical diagnosis in parkinsonism—a prospective study. Can J Neurol Sci. 1991;18(3):275–278
  16. Rosengren LE, Karlsson JE, Karlsson JO, Persson LI, Wikkelso C. Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSF. J Neurochem. 1996;67(5):2013–2018
  17. Urakami K, Wada K, Arai H, Sasaki H, Kanai M, Shoji M, et al. Diagnostic significance of tau protein in cerebrospinal fluid from patients with corticobasal degeneration or progressive supranuclear palsy. J Neurol Sci. 2001;183(1):95–98
  18. Van Geel WJ, Rosengren LE, Verbeek MM. An enzyme immunoassay to quantify neurofilament light chain in cerebrospinal fluid. J Immunol Meth. 2005;296(1/2):179–185
  19. Watanabe H, Saito Y, Terao S, Ando T, Kachi T, Mukai E, et al. Progression and prognosis in multiple system atrophy: an analysis of 230 Japanese patients. Brain. 2002;125(5):1070–1083
  20. Wenning GK, Ben SY, Magalhaes M, Daniel SE, Quinn NP. Clinical features and natural history of multiple system atrophy. An analysis of 100 cases. Brain. 1994;117(4):835–845
  21. Wenning GK, Tison F, BenShlomo Y, Daniel SE, Quinn NP. Multiple system atrophy: a review of 203 pathologically proven cases. Mov Disord. 1997;12(2):133–147
  22. Yazawa I, Giasson BI, Sasaki R, Zhang B, Joyce S, Uryu K, et al. Mouse model of multiple system atrophy alpha-synuclein expression in oligodendrocytes causes glial and neuronal degeneration. Neuron. 2005;45(6):847–859

PII: S0197-4580(06)00107-2

doi: 10.1016/j.neurobiolaging.2006.03.010

Neurobiology of Aging
Volume 28, Issue 5 , Pages 742-747 , May 2007

Article Tools

* Image Usage & Resolution